CN1262665C - 经过密码子最优化的乳头状瘤病毒序列 - Google Patents

经过密码子最优化的乳头状瘤病毒序列 Download PDF

Info

Publication number
CN1262665C
CN1262665C CNB018161081A CN01816108A CN1262665C CN 1262665 C CN1262665 C CN 1262665C CN B018161081 A CNB018161081 A CN B018161081A CN 01816108 A CN01816108 A CN 01816108A CN 1262665 C CN1262665 C CN 1262665C
Authority
CN
China
Prior art keywords
hpv
polynucleotide sequence
cell
sequence
codon
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB018161081A
Other languages
English (en)
Chinese (zh)
Other versions
CN1462309A (zh
Inventor
彼得·F·厄特尔
杰拉尔德·W·高夫
瓦尼塔·帕马
克里斯托弗·J·A·林
萨拉·M·沃尔科特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0017990.3A external-priority patent/GB0017990D0/en
Priority claimed from GB0025802A external-priority patent/GB0025802D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of CN1462309A publication Critical patent/CN1462309A/zh
Application granted granted Critical
Publication of CN1262665C publication Critical patent/CN1262665C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CNB018161081A 2000-07-21 2001-07-20 经过密码子最优化的乳头状瘤病毒序列 Expired - Fee Related CN1262665C (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0017990.3 2000-07-21
GBGB0017990.3A GB0017990D0 (en) 2000-07-21 2000-07-21 Papilloma virus sequences
GB0025802A GB0025802D0 (en) 2000-10-20 2000-10-20 Papilloma virus sequences
GB0025802.0 2000-10-20

Publications (2)

Publication Number Publication Date
CN1462309A CN1462309A (zh) 2003-12-17
CN1262665C true CN1262665C (zh) 2006-07-05

Family

ID=26244703

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB018161081A Expired - Fee Related CN1262665C (zh) 2000-07-21 2001-07-20 经过密码子最优化的乳头状瘤病毒序列

Country Status (22)

Country Link
EP (1) EP1301614B1 (enExample)
JP (1) JP2004504057A (enExample)
KR (1) KR100874552B1 (enExample)
CN (1) CN1262665C (enExample)
AT (1) ATE346947T1 (enExample)
AU (2) AU2001275695B9 (enExample)
BR (1) BR0112637A (enExample)
CA (1) CA2416488A1 (enExample)
CY (1) CY1106334T1 (enExample)
CZ (1) CZ2003180A3 (enExample)
DE (1) DE60124918T2 (enExample)
DK (1) DK1301614T3 (enExample)
ES (1) ES2277605T3 (enExample)
HK (1) HK1056195B (enExample)
HU (1) HUP0300745A3 (enExample)
IL (1) IL154009A0 (enExample)
MX (1) MXPA03000554A (enExample)
NO (1) NO20030219L (enExample)
NZ (1) NZ523683A (enExample)
PL (1) PL365385A1 (enExample)
PT (1) PT1301614E (enExample)
WO (1) WO2002008435A1 (enExample)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE50214379D1 (de) 2001-06-05 2010-05-27 Curevac Gmbh Stabilisierte mRNA mit erhöhtem G/C-Gehalt für die Gentherapie
WO2003018055A1 (en) * 2001-08-23 2003-03-06 Merck & Co., Inc. Vaccine using papilloma virus e proteins delivered by viral vector
DE10162480A1 (de) 2001-12-19 2003-08-07 Ingmar Hoerr Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen
AU2003219760A1 (en) * 2002-02-14 2003-09-04 Novavax, Inc. Optimization of gene sequences of virus-like particles for expression in insect cells
GB0222953D0 (en) * 2002-10-03 2002-11-13 Glaxo Group Ltd Novel Compounds
MXPA05010285A (es) 2003-03-24 2005-11-17 Merck & Co Inc Expresion optimizada de hpv 31 l1 en levadura.
GB0321615D0 (en) 2003-09-15 2003-10-15 Glaxo Group Ltd Improvements in vaccination
MY140664A (en) 2003-09-29 2010-01-15 Merck Sharp & Dohme Optimized expression of hpv 45 l1 in yeast
MY139500A (en) 2003-11-12 2009-10-30 Merck Sharp & Dohme Optimized expression of hpv 58 l1 in yeast
ES2343255T3 (es) 2004-03-24 2010-07-27 MERCK SHARP & DOHME CORP. Expresion optimizada del vph 52 l1 en levadura.
GB0617387D0 (en) * 2006-09-04 2006-10-11 Glaxo Group Ltd Synthetic gene
US8772256B2 (en) * 2006-11-30 2014-07-08 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Codon modified immunogenic compositions and methods of use
GB0700914D0 (en) * 2007-01-18 2007-02-28 Animal Health Inst Polynucleotides and uses thereof
RU2482189C2 (ru) 2007-01-30 2013-05-20 Трансген С.А. Полипептиды е2 папилломавируса, применяемые для вакцинации
EP2139515B2 (en) 2007-03-30 2023-12-20 The Research Foundation of the State University of New York Attenuated viruses useful for vaccines
GB0710538D0 (en) * 2007-06-01 2007-07-11 Glaxo Group Ltd Vaccine
EP3578205A1 (en) 2010-08-06 2019-12-11 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
CN103429606A (zh) 2010-10-01 2013-12-04 现代治疗公司 设计核酸及其使用方法
CA2831613A1 (en) 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
KR20190099538A (ko) 2011-10-03 2019-08-27 모더나 세라퓨틱스, 인코포레이티드 변형된 뉴클레오사이드, 뉴클레오타이드, 및 핵산, 및 이들의 용도
EP4144378A1 (en) 2011-12-16 2023-03-08 ModernaTX, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
AU2013243954A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
DK2922554T3 (en) 2012-11-26 2022-05-23 Modernatx Inc Terminalt modificeret rna
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
BR112016007255A2 (pt) 2013-10-03 2017-09-12 Moderna Therapeutics Inc polinucleotídeos que codificam receptor de lipoproteína de baixa densidade
CA2925021C (en) 2013-11-01 2025-05-06 Curevac Ag MODIFIED MESSENGER RIBONUCLE ACID (MRNA) WITH REDUCED IMMUNOSTIMULATING PROPERTIES
US11364292B2 (en) 2015-07-21 2022-06-21 Modernatx, Inc. CHIKV RNA vaccines
TW201718638A (zh) 2015-07-21 2017-06-01 現代治療公司 傳染病疫苗
WO2017070624A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Tropical disease vaccines
US11643441B1 (en) 2015-10-22 2023-05-09 Modernatx, Inc. Nucleic acid vaccines for varicella zoster virus (VZV)
MA45209A (fr) 2015-10-22 2019-04-17 Modernatx Inc Vaccins contre les maladies sexuellement transmissibles
CA3003678A1 (en) 2015-10-30 2017-05-04 Children's National Medical Center Generating hpv antigen-specific t cells from a naive t cell population
EP3538146A4 (en) 2016-11-11 2020-07-15 ModernaTX, Inc. INFLUENZA VACCINE
US11103578B2 (en) 2016-12-08 2021-08-31 Modernatx, Inc. Respiratory virus nucleic acid vaccines
WO2018170270A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Varicella zoster virus (vzv) vaccine
US11464848B2 (en) 2017-03-15 2022-10-11 Modernatx, Inc. Respiratory syncytial virus vaccine
WO2018170245A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Broad spectrum influenza virus vaccine
WO2018170256A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Herpes simplex virus vaccine
US10653767B2 (en) 2017-09-14 2020-05-19 Modernatx, Inc. Zika virus MRNA vaccines
WO2019148101A1 (en) 2018-01-29 2019-08-01 Modernatx, Inc. Rsv rna vaccines
US11351242B1 (en) 2019-02-12 2022-06-07 Modernatx, Inc. HMPV/hPIV3 mRNA vaccine composition
WO2020190750A1 (en) 2019-03-15 2020-09-24 Modernatx, Inc. Hiv rna vaccines

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5464936A (en) * 1990-12-21 1995-11-07 Cetus Oncology Corporation Compositions for identification of papillomavirus replication inhibitors
DE4123760C2 (de) * 1991-07-18 2000-01-20 Dade Behring Marburg Gmbh Seroreaktive Bereiche auf den HPV 16 Proteinen E1 und E2
DE69836206T2 (de) * 1997-02-07 2007-08-23 Merck & Co., Inc. Synthetische hiv gag gene
US6235523B1 (en) * 1998-09-04 2001-05-22 Connaught Laboratories Limited Vectors for DNA immunization against cervical cancer
AU772611B2 (en) * 1999-08-25 2004-05-06 Merck Sharp & Dohme Corp. Synthetic human papillomavirus genes

Also Published As

Publication number Publication date
CN1462309A (zh) 2003-12-17
CY1106334T1 (el) 2011-10-12
ES2277605T3 (es) 2007-07-16
NO20030219D0 (no) 2003-01-16
EP1301614B1 (en) 2006-11-29
DE60124918T2 (de) 2007-08-02
HUP0300745A2 (hu) 2003-08-28
NO20030219L (no) 2003-03-20
WO2002008435A1 (en) 2002-01-31
HK1056195B (en) 2007-06-22
CA2416488A1 (en) 2002-01-31
AU2001275695B2 (en) 2005-01-27
BR0112637A (pt) 2003-06-10
AU7569501A (en) 2002-02-05
CZ2003180A3 (cs) 2003-08-13
HK1056195A1 (en) 2004-02-06
DE60124918D1 (de) 2007-01-11
KR20030074586A (ko) 2003-09-19
ATE346947T1 (de) 2006-12-15
EP1301614A1 (en) 2003-04-16
DK1301614T3 (da) 2007-04-02
PT1301614E (pt) 2007-02-28
MXPA03000554A (es) 2004-12-13
AU2001275695B9 (en) 2005-05-26
JP2004504057A (ja) 2004-02-12
PL365385A1 (en) 2005-01-10
HUP0300745A3 (en) 2010-01-28
KR100874552B1 (ko) 2008-12-16
WO2002008435A8 (en) 2002-04-04
NZ523683A (en) 2004-08-27
IL154009A0 (en) 2003-07-31

Similar Documents

Publication Publication Date Title
CN1262665C (zh) 经过密码子最优化的乳头状瘤病毒序列
AU2001275695A1 (en) Codon-optimized papilloma virus sequences
CN113666990B (zh) 一种诱导广谱抗冠状病毒的t细胞疫苗免疫原及其应用
WO2020063370A2 (zh) 免疫组合物及其制备方法与应用
WO2004076645A2 (en) Compositions and methods for cytomegalovirus treatment
RU2323744C2 (ru) Вакцина против hcv
Massa et al. Antitumor activity of DNA vaccines based on the human papillomavirus-16 E7 protein genetically fused to a plant virus coat protein
US7132262B2 (en) Papilloma virus sequences
US20150132325A1 (en) Novel compositions and uses therefor
CN102286104B (zh) Hpv6型l2n120e7e6融合蛋白基因、表达载体、方法、菌株和用途
CN104628871A (zh) 一种重组法氏囊病蛋白工程疫苗的制备
EP1846026A2 (en) Anti-cancer dna vaccine employing plasmids encoding mutant oncoprotein antigen and calreticulin
CN100393878C (zh) 疫苗
US20090202584A1 (en) Treatment of epstein-barr virus-associated diseases
CA2395208A1 (en) Nucleic acid vaccination
CN117417457A (zh) PCV2和PCV3融合Cap蛋白二联亚单位疫苗及其制备方法和应用
RU2312896C2 (ru) Последовательность нуклеиновой кислоты, кодирующая белок gag вич-1, способ получения указанной последовательности, вектор, содержащий ее, белок, кодируемый ею, фармацевтическая композиция и их применение для профилактики и/или лечения вич-инфекции и спида
CN1772892A (zh) Hiv－1病毒样颗粒及其制备方法与用途
US20130017572A1 (en) Codon modified polynucleotide sequences for enhanced expression in a host system
CN115569189A (zh) 治疗hpv感染的疫苗组合
Mažeikė Generation of anticancer vaccine based on virus-like particles
Rainone ROLE OF THE MUCOSAE-ASSOCIATED EPITHELIAL CHEMOKINE (MEC/CCL28) IN THE MODULATION OF THE IMMUNE RESPONSE AGAINST VIRAL INFECTIONS
AU2006322645A1 (en) Treatment of Epstein-Barr Virus-associated diseases
CN101255434A (zh) 疫苗

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20060705

Termination date: 20100720